DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway
Study sponsor: Rhythm Pharmaceuticals, Inc. · RYTM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-08-04Actual
Enrollment · participants164Actual
Source updated2025-07-02Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.